The mean price target for the shares of Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) is at $9.13 while the highest price target suggested by the analysts is $13.00 and low price target is $6.00. The mean price target is calculated keeping in view the consensus of 8 brokerage firms.
The company’s mean estimate for sales for the current quarter ending Jun 16 is 58.93M by 7 analysts. The means estimate of sales for the year ending Dec 16 is 214.76M by 8 analysts.
The average estimate of EPS for the current fiscal quarter for Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) stands at $-0.13 while the EPS for the current year is fixed at $-0.60 by 7.00 analysts
The next one year’s EPS estimate is set at -0.43 by 8.00 analysts while a year ago the analysts suggested the company’s EPS at $-0.60. The analysts also projected the company’s long-term growth at 30.00% for the upcoming five years
In its latest quarter ended on 31 Mar 2016 , Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) reported earnings of $-0.28. The posted earnings missed the analyst’s consensus by $-0.04 with the surprise factor of -16.70%. In the matter of earnings surprises, the term ‘Cockroach Effect’ is often implied. Cockroach Effect is a market theory that suggests that when a company reveals bad news to the public, there may be many more related negative events that have yet to be revealed. In the case of earnings surprises, if a company is suggesting a negative earnings surprise it means there are more to come.
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) traded down -4.32% during trading on Friday, hitting $8.89 . The stock had a trading volume of 4.7 M shares. The firm has a 50 day moving average of $7.78 and a 200-day moving average of $6.41. The stock has a market cap of $1.61B. On Aug 28, 2015 the shares registered one year high at $10.07 and the one year low was seen on Feb 11, 2016.
On June 8, 2016 Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) announced that it will host an Analyst & Investor Day for its research analysts and institutional investors on Friday, June 17 at 8:30 a.m. (EDT) in New York City. Paris Panayiotopoulos, president and chief executive officer of ARIAD, will host the event along with other key members of ARIAD senior management. The meeting will focus on ARIAD’s completion of its corporate strategic review, as well as provide an update on continued progress in its research and development and commercial programs. Expert medical leaders in the fields of chronic myeloid leukemia and non-small cell lung cancer will be featured speakers and discussants at the meeting.
0 yorum:
Yorum Gönder